Exposure to chemotherapy promotes the exit of specific subpopulations of BMDCs with angio-supportive activity.
Notch in BMDCs is required for the exit of these cells from the bone marrow and for chemotherapy-enhanced angiogenesis in tumors.
Host responses to chemotherapy can induce resistance mechanisms that facilitate tumor regrowth. To determine the contribution of bone marrow–derived cells (BMDCs), we exposed tumor-bearing mice to chemotherapeutic agents and evaluated the influx and contribution of a genetically traceable subpopulation of BMDCs (vascular endothelial–cadherin-Cre-enhanced yellow fluorescent protein [VE-Cad-Cre-EYFP]). Treatment of tumor-bearing mice with different chemotherapeutics resulted in a three- to 10-fold increase in the influx of VE-Cad-Cre-EYFP. This enhanced influx was accompanied by a significant increase in angiogenesis. Expression profile analysis revealed a progressive change in the EYFP population with loss of endothelial markers and an increase in mononuclear markers. In the tumor, 2 specific populations of VE-Cad-Cre-EYFP BMDCs were identified: Gr1+/CD11b+ and Tie2high/platelet endothelial cell adhesion moleculelow cells, both located in perivascular areas. A common signature of the EYFP population that exits the bone marrow is an increase in Notch. Inducible inactivation of Notch in the EYFP+ BMDCs impaired homing of these BMDCs to the tumor. Importantly, Notch deletion reduced therapy-enhanced angiogenesis, and was associated with an increased antitumor effect of the chemotherapy. These findings revealed the functional significance of a specific population of supportive BMDCs in response to chemotherapeutics and uncovered a new potential strategy to enhance anticancer therapy.
Anticancer treatment, including chemotherapy, vascular disruptive agents, antiangiogenic agents, and even surgery, induces host responses that can reduce the efficacy of therapy.1-9 These host responses promote changes in the (tumor) microenvironment including the influx of bone marrow–derived cells (BMDCs), as well as mesenchymal, inflammatory, and vascular cells, to the tumor. These cells might partially negate the anticancer effects of treatment by providing survival signals and inducing angiogenesis.1-3,7,9-13 In particular, the increase of BMDCs after chemotherapy has been recently considered as an important cause for reduced responsiveness to chemotherapy and for enhanced angiogenesis.
Our understanding of vascular growth in tumors has evolved from the simple model of endothelial sprouting into a multifaceted process that also includes local activation and support by additional cell types. Specifically, BMDCs featuring characteristics and properties of macrophages have been found to support angiogenesis in various mouse models.14 Gr1+ and CD11b+ cells, including Tie2-expressing monocytes and tumor-associated macrophages (TAMs), can catalyze angiogenesis by producing proangiogenic factors and/or function as “vascular bridges” by guiding and connecting the filopodia tips of nascent vessels.7,12,15-19 Selective loss of these cells results in reduced tumor growth and impaired angiogenesis.11 However, whether these BMDCs contribute to angiogenesis by direct incorporation into the vascular wall or whether they assist in other aspects of vascular morphogenesis has been the subject of lively debate. To date, the relative contribution of BMDCs to tumor vasculature has been reported to range from <0.1% up to >50%,20-23 and there is still a lack of consensus on the definition, origin, and specific function of “the endothelial progenitor cell.” This lack of a defined phenotype is partially due to the fact that these cells most likely change their surface markers as they egress the bone marrow, circulate, and enter the tumor microenvironment. Most articles define endothelial progenitor cells as BMDCs expressing vascular markers, like vascular endothelial–cadherin (VE-cadherin), vascular endothelial growth factor receptor 2 (VEGFR-2), CD133, and CD31, in the absence of hematopoietic markers.24 However, a significant body of evidence indicates that these cells are in fact bone marrow–derived (BMD) proangiogenic hematopoietic cells and lack true endothelial properties.25
The aims of this study were to determine the contribution of the chemotherapy-induced influx of BMD angio-supportive cells to chemoresistance in solid tumors, to understand their relationship to previously described populations, and to gain additional information as to the signaling pathways that regulate their function.
Materials and methods
Studies were conducted in accordance with the Animal Research Committee guidelines established by the University of California, Los Angeles and the University Medical Center Utrecht, The Netherlands. VE-cadherin-Cre/R26R mice, VE-cadherin-Cre/EYFP mice, inducible VE-cadherin-Cre-ERT2/enhanced yellow fluorescent protein (EYFP) mice, inducible VE-cadherin-Cre-ERT2/R26R (CIVE) mice, and inducible VE-cadherin-Cre-ERT2/NOTCH/EYFP mice were described elsewhere.26-31 See supplemental Table 1 for an overview. Six-week-old C57BL/6 mice (Charles River) were lethally irradiated (1000 rad) and transplanted with 5 × 106 bone marrow cells from the different donor mice. Tamoxifen was prepared as described in Monvoisin et al,30 and 1 mg was injected intraperitoneally every other day for the times indicated.
Mammary epithelial tumor cells from MMTV-c-neu transgenics (mixed background 129/C57BL) were isolated, characterized, and injected orthotopically (106) into nude mice after transplantation with bone marrow cells from VE-cadherin constitutive, inducible, or control mice. Lewis lung carcinoma (LLC) cells were subcutaneously (0.7 × 106) injected into C57BL/6 mice 3 weeks after irradiation and transplantation with bone marrow cells from different donor mice. C26 colorectal cancer cells were subcutaneously (1 × 106) injected into BALB/c mice (Charles River). Tumor size was assessed with calipers using the formula width2 × length × 0.5. Treatment was initiated when tumors reached 100 mm3. Mice received intraperitoneally 6 mg/kg cisplatin or 40 mg/kg paclitaxel or a vehicle. Tumors were harvested 1 and 8 days after treatment. Blood was obtained by cardiac puncture, followed by perfusion with phosphate-buffered saline/2 mM EDTA (37°C) for 3 to 5 minutes before harvesting part of the femur and tumor for fluorescence-activated cell sorter (FACS) analysis. Thereafter, mice were perfused for 3 minutes with 1% paraformaldehyde/2 mM EDTA (37°C) and organs and tumors were fixed in 4% paraformaldehyde.
Flow cytometry analysis
Single-cell suspensions were minced, incubated at 37°C for 15 minutes in collagenase (1 mg/mL)/Dnase (0.4 mg/mL), and filtered with 100- and 40-μm filters (BD Biosciences). Bone marrow cells were either flushed from the femur or isolated from the blood or from the tumors. Cells were analyzed on a FACS LSR II with monoclonal antibodies or appropriate isotype controls as indicated in the supplemental Methods on the Blood website. Cells were sorted on a FACSAria using the Ag-presenting cell–conjugated platelet endothelial cell adhesion molecule (PECAM), EYFP, and 7-aminoactinomycin D Cells were gated based on size, viability, PECAM, and/or EYFP expression. FACS analysis on embryonic tissue was performed as previously described in Zovein et al.28
Vibratome sections (300 μm) were incubated with 1:400 PECAM-1 rat anti-mouse antibody (BD Pharmingen); smooth-muscle actin anti-mouse (Sigma) and 1:200 Cy3 or Cy5 secondary antibody (Jackson ImmunoResearch); TO-PRO-3 (Invitrogen); or DAPI (4,6 diamidino-2-phenylindole) (Sigma). Confocal laser scanning microscopy evaluation was performed. Immunohistochemistry on CD31 and β-galactosidase (β-gal) staining were performed as described in Alva et al29 and in supplemental Methods.
Real-time reverse transcription–polymerase chain reaction (RT-PCR)
Total RNA was extracted from FACS cells using TRIzol (Invitrogen). Complementary DNA was generated by reversed transcription in 20 μL reaction mixture at 50°C for 1 hour. Half of that volume was mixed with SYBR Green 1 Buffer (QIAGEN). Complementary DNA was amplified by RT-PCR using specific primers. Emission of SYBR Green 1 incorporation was quantified using the threshold cycle value. Results presented are from 4 independent experiments, normalized to endogenous Hprt. Primers are shown in the supplemental Material.
Contribution of the different VE-cadherin–expressing cells to the tumor vasculature of unperturbed tumors
We used several transgenic mouse models to genetically trace BMD-VE-cadherin–expressing cells. First we used the constitutive VE-cadherin-Cre/R26R model. In these mice, the endothelium and a large part of the hematopoietic compartment is β-gal–positive, as embryonic VE-cadherin–expressing cells give rise to both endothelial and hematopoietic progeny28-30 (Figure 1Aa). In c-neu, transformed mammary epithelial tumor β-gal–positive cells were found both lining and associated with blood vessels (Figure 1Ab). Using VE-cadherin-Cre/EYFP mice, FACS analysis showed that 60% of all cells in the tumor were EYFP-positive (Figure 1B). To investigate the contribution of specifically BMD-VE-cadherin–expressing cells, we transplanted the bone marrow of VE-cadherin-Cre/R26R mice into lethally irradiated wild-type C57BL/6 mice. In the bone marrow of transplanted mice, again, 50% of the cells expressed β-gal, mostly coexpressed with CD45 (>90%) (Figure 1Ac and supplemental Figure 1A). Tumors showed a clear influx of β-gal–positive cells, mainly CD45+; only a very small subset of the β-gal–positive cells was actually part of the endothelium (Figure 1Ad). CD31 costaining of these sections clearly demonstrates that the recombination mainly occurs in the cells surrounding the vessels and only 0.02% of all vessel lining cells expressed β-gal (Figure 1C-E). FACS analysis showed a contribution of 50% of EYFP+ cells in the tumor (Figure 1B), although we did not discriminate between circulating and tumor-resident inflammatory cells.
To bypass the ability of embryonic VE-cadherin–expressing cells to give rise to the broad cohort of hematopoietic progeny, we next used tamoxifen-inducible CIVE mice. After tamoxifen induction, a specific and widespread recombination can be found in the endothelium with very limited expression in the hematopoietic lineage.28-30 Using this strategy, we were able to identify a relative minor subpopulation (0.3% ± 0.1%) that was positive for β-gal (supplemental Figure 1B). As predicted, many of these cells were found lining blood vessels by virtue of VE-cadherin expression (endothelial cells), but others (exclusively in the bone marrow) were nonvessel-associated cells (Figure 1Ae and supplemental Figure 1C-D). In subcutaneously implanted tumors, recombined VE-cadherin–expressing cells were found lining the vasculature32 and a very small population of nonvascular cells (Figure 1Af). FACS analysis showed that the contribution of the VE-cadherin-Cre–expressing population, as per recombination of the reporter EYFP+, was remarkably reduced to, on average, 0.5% compared with the constitutive model (Figure 1B).
To distinguish between BMD-adult-VE-cadherin–expressing cells and peripheral-VE-cadherin–expressing cells, we next performed 2 different transplantation experiments. First we transplanted the bone marrow of CIVE mice into lethally irradiated wild-type C57BL/6 mice. We found 0.3% β-gal–expressing cells in the bone marrow (Figure 1Ag and supplemental Figure 1B). Tumors in these mice showed a limited influx of mainly nonvessel-associated positive cells (Figure 1Ah). In total, the influx of EYFP+ cells was similar to the previous, nontransplanted CIVE model (0.5%). However, most cells were in the nonvessel-associated compartment (Figure 1B and 1Ah). Next we transplanted bone marrow from wild-type BL/6 mice into lethally irradiated CIVE mice. As expected, bone marrow from these mice contained no β-gal–expressing cells (Figure 1Ai). When we analyzed tumors growing in these mice, the endothelium in tumor vessels was clearly β-gal–positive and no nonvessel-associated β-gal–positive cells were detected (Figure 1Aj). CD31 immunohistochemistry of previously X-gal–stained sections demonstrated that the recombination occurred in the tumor endothelium (Figure 1F). In total, 0.1% of all cells in the tumor were found to be positive in this model (Figure 1B).
Taken together, in unperturbed tumors the vast majority of the tumor endothelium is derived from adult, non-BMD-VE-cadherin–expressing cells. However, a very small population of BMD-VE-cadherin–expressing cells was found to incorporate the vascular wall of tumors at a proportion of 0.02%; this was not found in normal tissues.
Chemotherapy-enhanced angiogenesis is associated with an influx of BMD-VE-cadherin–expressing cells
We next questioned whether challenging the host with maximum tolerated dose chemotherapy would affect the influx of VE-cadherin BMDCs in the tumor. We transplanted the bone marrow from tamoxifen-inducible VE-cadherin-Cre-ERT2/EYFP (CIVE/EYFP) mice into wild-type, lethally irradiated C57BL/6 mice. These animals were subsequently treated with tamoxifen to reveal the VE-cadherin–expressing population, injected with tumor cells, and subjected to chemotherapy (Figure 2A).
We first accessed the percentage of endothelial cells after different types of chemotherapy in 2 different mouse tumor models. C57BL/6 mice bearing LLC tumors and BALB/c mice bearing C26 tumors were treated with either cisplatin, paclitaxel, or a vehicle (Figure 2B and supplemental Figure 2A). In both models, a significant increase in endothelial cells in the tumor was noted after chemotherapy (Figure 2C-F), despite an initial decrease in tumor growth (Figure 2B). Confocal microscopy confirmed the presence of more vascular structures 8 days after chemotherapy (supplemental Figure 2B). Notably, C26 cells are intrinsically resistant to paclitaxel (supplemental Figure 2A).
This burst in angiogenesis was temporally correlated with a significant increase in the influx of EYFP+ BMDCs in the tumor after treatment with chemotherapy (Figure 2G-H and supplemental Figure 2C). A slight increase in EYFP+ cells in the circulation was detected 1 day after chemotherapy (supplemental Figure 2D-E). The influx of EYFP+ cells was specific for tumor tissue and, as in control organs like the lung, liver, and spleen, hardly any EYFP+ cells were detected and there were no differences between the treated and untreated mice (supplemental Figure 2F). In summary, systemic treatment with chemotherapy strongly increased the influx of VE-cadherin–expressing BMDCs in tumors.
Specific tumor influx of 2 subpopulations of VE-cadherin–expressing BMDCs
Confocal microscopy revealed that EYFP+ cells in the tumor were found in close association with tumor vessels, whereas in areas without vessels hardly any EYFP+ cells were noted (Figure 3A and supplemental Figure 3A). After chemotherapy, more EYFP+ cells were identified per vascular structure than in the untreated tumors (supplemental Figure 3B). Although the EYFP+ cells clustered around the vessels, only a few EYFP+/PECAMlow cells were seen (Figure 3A). In order to further characterize the influx of EYFP+ cells, we analyzed the phenotype of the EYFP+ cells in the bone marrow of these transplanted mice (supplemental Table 2). As noted before, the EYFP+ population constituted only 0.3% of all bone marrow cells. Eighty percent of the EYFP+ cells expressed the hematopoietic marker CD45 and were divided into an endotheliallike population coexpressing VE-cadherin, PECAM, and VEGFR-2 and a population expressing monocyte/macrophage markers CD11b and Gr1 (Figure 3B-C). After cisplatin or paclitaxel chemotherapy, an increase in both EYFP+/PECAMlow cells and in EYFP+/Gr1+/CD11b+ cells was seen in the tumor (Figure 3D,F), and both cell types are known for their proangiogenic properties.7,10,11,15-19,23,24,32-34
In the untreated tumors, on average 0.45% of all PECAMlow cells were EYFP-positive. However, the majority of these cells coexpressed CD45 and therefore belongs to the hematopoietic lineage. When focusing on only the PECAMlow/CD45− cells, only 0.002% of these cells were yellow fluorescent protein (YFP)–positive. Remarkably, after treatment with chemotherapy this percentage increased to 0.1% upon cisplatin, and 0.16% upon paclitaxel, exposure (Figure 3D-E). This relative increase in EFYP+/PECAM+ cells exceeded the increase of the total EYFP+ cells (2.2- and 2.6-fold, respectively), suggesting a specific influx of PECAMlow/CD45−/EYFP cells. The specificity was further supported by our findings in the constitutive VE-cadherin-Cre/EYFP model. Using the bone marrow from these mice resulted in much higher levels of EYFP cells in the tumor when compared with the inducible model (supplemental Figure 3C). However, no overall increase in EYFP+ cells was seen after chemotherapy (supplemental Figure 3C), showing that there is no general increased influx of BMDCs. We did find a specific increase in EYFP/PECAMlow cells with borderline significance (P = .05) after chemotherapy (supplemental Figure 3D).
In addition to the influx of PECAMlow/EYFP cells, 1 day after chemotherapy a significant increase of EYFP/Gr1+/CD11b+ cells was noted (Figure 3F). Interestingly, there was no increase in the overall Gr1+/CD11b+ population (Figure 3G). This shows a specific influx of the EYFP/Gr1+/CD11b+ cells and suggests that these cells actually might be different from their counterparts that did not express VE-cadherin. Notably, after 8 days, the EYFP/Gr1+/CD11b+ levels were similar in all groups, with an average contribution of 0.01% (standard deviation 0.07). Because the total number of EYFP cells in the tumor increased later on, we predicted that this population will lose these specific markers over time. In addition to directly enhancing angiogenesis, Gr1+/CD11b+ cells have been found to promote maturation of vessels via better pericyte coverage.35 We found a significant increase in pericyte coverage of tumor vessels 8 days after chemotherapy (supplemental Figure 4A) compared with the untreated tumors, with only a small part of the smooth-muscle actin+ cells being EYFP-positive (supplemental Figure 4B). Furthermore, there was a borderline significant increase in neuron-glia2–positive cells 8 days after chemotherapy (data not shown).
VE-cadherin-BMDC–derived cells exhibit phenotypic changes as they exit the bone marrow
Because the EYFP/PECAMlow population exhibited the most significant change in the tumors, we followed this population while in transit to the tumor. FACS analysis revealed that this group of cells made up 2.6% of the CD45− population (Figure 4A). Interestingly, in the bone marrow they expressed high levels of PECAM. In the bloodstream, EYFP cells made up 0.47% of the circulating nucleated cells (Figure 4B). In the tumor, the percentage of these cells ranged from 0.3% (vehicle treated) to 1.6% (after chemotherapy treatment) (Figure 4C). Importantly, the level of PECAM was heterogeneous but continued to decrease in the tumors (Figure 4C). We characterized the EYFP population in the 3 different compartments through gene expression profiling. In the bone marrow, we compared the EYFP−/PECAM+ bone marrow cells (Figure 4E) with the EYFP/PECAM+ bone marrow cells (Figure 4F). As can be observed, the expression profile of several endothelial markers showed a significant level of similarity. This pattern changed as the EYFP population reached the circulation (Figure 4G). In particular, levels of PECAM, VE-cadherin, and VEGFR-2 decreased, while Notch1, Notch ligand Δ-like 4 (Dll4), and Tie2 increased. As the population reached the tumor, a selective increase of MRC-1, a molecule typically expressed by macrophages, was noted (Figure 4H).
This analysis revealed that the genetically traced EYFP population changes drastically during its mobilization from the bone marrow, through the circulation, to the tumor (Figure 4D). In general, the endothelial markers (gray) tend to decrease, whereas the macrophage markers (black) tend to increase during this process (Figure 4E-H). Interestingly, Notch1 messenger RNA levels were selectively induced in the subgroup that egressed the bone marrow and gained access to the circulation (Figure 4G). This suggested that Notch signaling might likely participate in the egression of EYFP cells from the bone marrow.
Notch1 in EYFP cells is critical for the egression of these cells from the bone marrow, and its absence enhances response to chemotherapy
To determine the relevance of Notch signaling in the regulation of chemotherapy-induced egression of the subpopulations of BMDCs, we next used bone marrow from VE-cadherin-Cre-ERT2/NOTCH−/fl/EYFP mice and compared these results with the transplantation experiment using the CIVE mice (Figure 5A). These experiments enabled inducible Notch deletion concurrent with EYFP expression upon tamoxifen treatment (supplemental Figure 5). We found similar levels of EYFP cells in the bone marrow (Figure 5B), but significantly lower levels of EYFP cells were circulating in the Notch knockout (KO) mice (Figure 5C) after 8 days of treatment with either the vehicle or cisplatin. Notably, in the CIVE mice at day 1, a (borderline) significant increase was seen after treatment with chemotherapy (supplemental Figure 2); this was not detected in the Notch KO mice (data not shown). Thus, defective Notch signaling does not result in differences in the viability of EYFP+ cells within the bone marrow, but Notch is necessary for the egression of EYFP cells from the bone marrow. To exclude that chemotherapy itself influenced Notch signaling in EYFP cells, we performed RT-PCR on Notch, Dll4, and the downstream targets Hes1 and Hey1 in the EYFP+ cells with and without chemotherapy. We found no differences in Notch or Dll4 messenger RNA levels after treatment with cisplatin (supplemental Figure 6). In unstimulated EYFP cells, Hes1 or Hey 1 could not be detected; however, after plating the cells on JagFc both genes were induced in a manner that was indistinguishable in each of the groups (vehicle or cisplatin) (supplemental Figure 6).
In the vehicle-treated mice, we found reduced tumor growth in animals with deleted Notch in the bone marrow (Figure 5D). Moreover, the antitumor effect of cisplatin was greatly enhanced when Notch was deleted and tumor growth remained suppressed even 8 days after treatment (Figure 5D). Consistent with the finding that Notch is required for the EYFP cells’ egression from the bone marrow, we found only traces of EYFP cells in the tumors of these mice (Figure 5E-F). Furthermore, there was no increase in EYFP cells after chemotherapy (Figure 5E-F). Finally, the number of endothelial cells in the tumor was markedly reduced in mice with Notch-deleted VE-cadherin BMDCs and poor angiogenic activity was noted after chemotherapy (Figure 5E,G). Notably, pericyte coverage in these tumors was at best marginal (supplemental Figure 7). These findings indicate that this small subpopulation of VE-cadherin+ BMDCs is responsive to chemotherapy and plays a critical role in stimulating angiogenesis, vessel maturation, and tumor growth.
Finally, we performed an additional experiment in which the deletion of Notch1 was done 2 days after tumor inoculation (Figure 6A). This protocol allowed for egression of BMDCs during the initial days of tumor growth. In these experiments, similar results to those with pretumor deletion of Notch1 were also obtained. Angiogenesis, influx of EYFP cells, and tumor growth were reduced in the mice where the deletion of Notch1 was induced shortly after tumor transplantation (Figure 6B-D). Overall, the findings indicate that the early egression of EYFP cells was either not sufficient for stimulating angiogenesis or that a continuous egression was necessary to support angiogenesis and tumor growth.
A rapidly increasing body of evidence supports the notion that chemotherapy can evoke a host-repair response in which BMDCs are recruited to the tumor. There, BMDCs might facilitate regrowth of the tumor through negating the anticancer effects of chemotherapy.1-9 Research specifically identifying relevant subpopulations of chemotherapy-induced BMDCs has been hampered by phenotypic changes as BMDCs migrate from the bone marrow into the circulation and finally into the tumor microenvironment.
Our study used unique mouse models to lineage trace the BMD-VE-cadherin–expressing cells into the tumor, thereby bypassing phenotypical changes in this population over time. Using the inducible VE-cadherin/EYFP/Cre model, we focused on the small population (0.3%) of adult BMDCs that expressed VE-cadherin in the bone marrow. At least 2 subpopulations could be discriminated. Both were recruited to the tumor microenvironment, and the recruitment was clearly enhanced after chemotherapy, which coincided with an almost twofold increase in endothelial cells and an increased vascular density in the tumor 8 days after chemotherapy. The vast majority of the EYFP cells in the tumor was located perivascularly and did not appear to be incorporated in the vasculature. In fact, although they express VE-cadherin at some point in the bone marrow, these cells are myeloid in nature as per their phenotypic and functional features and are not endothelial cell progenitors.
Our findings are in line with other studies showing that a heterogeneous population of BMDCs is found to infiltrate the tumor in response to therapy and interferes with response. We now show that both the PECAMlow population and the CD11b+/Gr1+ population are in fact derived from the adult VE-cadherin–positive BMDCs, which therefore clearly represent a small but biologically relevant constituency of cells in the bone marrow. Interestingly, once in the tumor, these cells also express high levels of Tie2 and MRC-1, suggesting a likely overlap with the previously described TAM population.6 Previously, vascular disruptive agents, radiotherapy, and chemotherapy were found to recruit both endothelial cell progenitor cells,1-4 as hematopoietic cells including Tie2-expressing monocytes,18 TAMs,6 and CD11b+ myelomonocytic cells.5 Importantly, it was shown that targeting both the endothelial as well as the myeloid populations has an additive effect and the influx of CD11b/Gr1–positive cells mediates the refractoriness of tumors to antiangiogenic therapy.7,11,36 This suggests shared properties and perhaps redundancy between the different pathways and populations of BDMCs in tumor angiogenesis. It has been further demonstrated that recruitment of BMDCs could be prevented by either targeting the CXC chemokine receptor 4/stromal cell derived factor 1 axis,1,2,4 the VEGF pathway,1 or the colony stimulating factor 1 receptor.6 The present study adds Notch1 to this panel of therapeutic targets. Mechanistically, we found that Notch1 is critical for the egression of this population from the bone marrow and that this population, albeit small, holds biological significance in both tumor growth and therapeutic response.
It is evident that Notch ligands and receptors play an important role in the differentiation and function of the vasculature. Mice with deficiencies in Notch signaling display severe vascular defects, and haploinsufficiency of Dll4 results in embryonic lethality.37-39 Furthermore, Notch signaling in BMD-progenitor cells is important for their proangiogenic effect in both tumor angiogenesis and wound healing.40,41 In contrast, a role of Notch signaling in resistance to chemotherapy is less well established. Notch is a regulator of cancer stem cell programming and contributes to the epithelial-to-mesenchymal transition, both associated with anticancer drug resistance.42,43 Therefore, targeting Notch could be a novel approach to overcoming the drug resistance of cancer cells by reducing cancer stem cells or epithelial-to-mesenchymal transition processes. Our data revealed an additional Notch-regulated mechanism of chemoresistance through the regulation of angio-supportive BMDC exit from the bone marrow. Strikingly, by specifically preventing the incorporation of these cells into the tumor microenvironment, a significant reduction in angiogenesis and tumor growth was noted. Several Notch inhibitors have been tested for antitumor effects in in vivo models and were shown to be additive to various types of chemotherapy.44,45 In addition, Notch inhibition was also found to act synergistically with other antiangiogenic agents.46 However, using Notch as a pharmacological target to enhance chemotherapy efficacy has been challenging due to (gastrointestinal) toxicity.47
Our findings highlight the importance of specific BMDCs in chemoresistance. Generally, the term “chemoresistance” is used to characterize tumor cell intrinsic mechanisms to neutralize the effects of chemotherapy. However, in the past decade, tumor cell extrinsic mechanisms of chemoresistance have been reported. In particular, inflammatory cells and other constituents of the tumor microenvironment all have been shown to render tumors insensitive to chemotherapy as part of a “host response to therapy,” even when tumor cells themselves were sensitive to chemotherapy.48 Thus, the overall benefit of a treatment is determined by the ratio of the sensitivity of cancer cells to the cytotoxic effects of chemotherapy and the counteracting host responses. In the case of an intrinsic resistant tumor, this could potentially even lead to enhanced tumor growth by having only the tumor promoting effects.49,50 Here we show that chemotherapy activates a host response mediated by a specific population of VE-cadherin–expressing BMDCs. This population changes while in transit and acquires some of the features previously associated with TAMs and CD11b/Gr+, indicating that these are likely to be the same. In addition, our findings further uncovered the relevance of Notch1 in the egression of these cells and indicate that this might be a potential target to improve chemotherapeutic treatment.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
The authors thank Michelle Steel for her technical assistance, the Tissue Procurement Core Laboratory Shared Resource, and the FACSCalibur Flow Cytometric Facility at the University of California, Los Angeles.
This work was supported by the National Institutes of Health National Cancer Institute (HL085618); California Institute for Regenerative Medicine Award (RB1-01328); and a grant from the Jonsson Cancer Center Foundation.
Contribution: J.M.L.R., H.H., E.E.V., and M.L.I.-A. designed the research; J.M.L.R., H.H., L.G.M.D., A.M., C.L.B., M.v.A., T.F.L, and J.J.H. performed the experiments; F.R. provided the Notch floxed mouse; J.M.L.R., H.H., T.F.L., E.E.V., and M.L.I.-A. analyzed the data; and J.M.L.R., E.E.V., and M.L.I.-A. wrote the paper.
Conflict-of-interest disclosure: The authors declare no competing financial interests.
The current affiliation for A.M. is Institute of Physiology and Cell Biology, National Center for Scientific Research, University of Poitiers, Poitiers, France.
Correspondence: M. Luisa Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, Biomedical Sciences/Orthopaedic Hospital Research Building–Room 447, UCLA, Los Angeles, CA 90095-1570; e-mail: firstname.lastname@example.org.
E.E.V. and M.L.I.-A. contributed equally to this study.